Effect of SAR302503 on ECG Activity in Patients With Solid Tumors

NCT ID: NCT01836705

Last Updated: 2025-03-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-05-31
• Study Completion Date: 2014-05-31

Brief Summary

Primary Objective:

• To assess the effect of SAR302503 (500 mg) administered as 14-day repeated doses on the QTcF interval compared to 1-day placebo in patients with advanced solid tumors.

Secondary Objectives:

• To assess the effect of SAR302503 administered as 14-day repeated doses on heart rate (HR), QT, QTcB, and QTcN, PR and QRS compared to placebo.
• To assess the clinical and laboratory safety of SAR302503
• To document the plasma concentrations of SAR302503 at the time of ECG investigation.
• To explore the Pharmacokinetic/Pharmacodynamic relationship between SAR302503 concentration and QTcF
• To explore antitumor activity

Detailed Description

Total 7-10 weeks if not progressing to Segment 2. Segment 2 will be additional in 28-day cycles.

Conditions

Neoplasm Malignant

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Single-sequence

SAR302503 Placebo (1 day)-SAR302503 (500 mg, oral, qd, 14 days)

Group Type: EXPERIMENTAL

SAR302503 (TG101348)

Intervention Type: DRUG

Pharmaceutical form:capsule

Route of administration: oral

Placebo SAR302503

Intervention Type: DRUG

Pharmaceutical form:capsule

Route of administration: oral

Panolosetron

Intervention Type: DRUG

Pharmaceutical form:solution

Route of administration: intravenous

Interventions

SAR302503 (TG101348)

Pharmaceutical form:capsule

Route of administration: oral

Intervention Type: DRUG

Placebo SAR302503

Pharmaceutical form:capsule

Route of administration: oral

Intervention Type: DRUG

Panolosetron

Pharmaceutical form:solution

Route of administration: intravenous

Intervention Type: DRUG

Other Intervention Names

Aloxi®

Eligibility Criteria

Inclusion Criteria

• Histologically or cytologically confirmed advanced solid malignancy that is metastatic or unresectable, and for which standard curative measures do not exist

Exclusion Criteria

• Prior history of torsades de pointe, or congenital long QT syndrome.
• Conditions with screening ECG in which repolarization is difficult to interpret, or showing significant abnormalities. This includes, but is not limited to: High degree atrioventricular (AV) block, pacemaker, atrial fibrillation or flutter
• Screening ECG with QTc B or QTc F ≥480 msec (within 8 days of Day-1)
• Significant hypokalemia at screening (K+ <3.5 mmol/L) (within 8 days of Day-1)
• Significant hypomagnesemia at screening and inclusion (Mg++ <0.7 mmol/L) (within 8 days of Day -1)
• Patient receives (and cannot discontinue), or is scheduled to receive, a concomitant treatment known to carry a risk of both QT prolongation and torsade de pointe for 2 weeks before Day 1 and for the duration of Segment 1
• Absence of completion of all prior chemotherapy, biological therapy, hormonal therapy, targeted non-cytotoxic therapy ≥3 weeks; and radiotherapy ≥2 weeks prior to inclusion.
• Patients with uncontrolled brain metastases or primary brain tumor. Patients with brain metastasis are considered eligible if the patient has not received radiation therapy for brain metastasis within 2 weeks of enrollment and has been on a stable dose of steroids for ≥ 2 weeks.
• Participation in any study of an investigational agent (drug, biologic, device) within 30 days prior to initiation of study drug, unless during non-treatment phase.
• Anticipation of need for a major surgical procedure or radiation therapy during the study treatment.
• Concurrent treatment in another clinical trial or with any other cancer therapy including chemotherapy, biological therapy, hormonal therapy, radiotherapy, chemoembolization, cryotherapy, targeted non-cytotoxic therapy or patients planning to receive these treatments during the study.
• Inadequate organ function as defined by:
• Absolute neutrophil count (ANC) <1.5 X 10^9/L
• Platelet count <100 X 10^9/L
• Hemoglobin: <9 g/dL
• Serum creatinine >1.5 x the upper limit of normal (ULN)
• Serum amylase or lipase >1.5 x ULN
• Total bilirubin >1.5 x ULN
• Aspartate aminotransferase or alanine aminotransferase ≥2.5 x ULN
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) >2 at study entry.
• Uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3 months prior to initiation of study drug.
• Ongoing or recent history (within 3 months of Day 1 Segment 1) of clinically significant dysrrhythmia.
• Patients taking a beta blocker within 7 days to Day 1 Segment 1 and during Segment 1
• Other concurrent serious illness or medical condition, including active infection or HIV disease.
• Patients with known active (acute or chronic) Hepatitis A, B, C, and hepatitis B and or C carriers. Prior history of chronic liver disease.
• Patients with history of partial or total gastrectomy, or, if in the opinion of the investigator, have any other disorder that would inhibit absorption of oral medications.
• Any severe acute or chronic medical, neurological, or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, may interfere with the informed consent process and/or with compliance with the requirements of the study, or may interfere with interpretation of study results and, in the Investigator's opinion, would make the patient inappropriate for entry into this study.
• Contra-indications for palonosetron.
• Use of drugs or herbal agents known to be at least moderate inhibitors or inducers of CYP3A4, sensitive CYP3A4 substrate, or CYP3A4 substrate with narrow therapeutic index, within 2 weeks of Day 1 and during study.
• Concomitant treatment with H2-blockers is not allowed within 7 days prior to Day 1 Segment 1 and during entire study.
• Known hypersensitivity to any excipients in IMP formulations.
• Pregnant or lactating females
• Women of childbearing potential, unless using effective contraception (other than oral contraceptives) while on study drug. Men who partner with a woman of childbearing potential, unless they agree to use effective contraception while on study drug

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bristol-Myers Squibb

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Sciences & Operations

Role: STUDY_DIRECTOR

Sanofi

Locations

Investigational Site Number 840003

Los Angeles, California, United States

Investigational Site Number 840007

Augusta, Georgia, United States

Investigational Site Number 840002

Detroit, Michigan, United States

Investigational Site Number 840001

St Louis, Missouri, United States

Investigational Site Number 840004

Cincinnati, Ohio, United States

Investigational Site Number 840005

Philadelphia, Pennsylvania, United States

Investigational Site Number 840006

San Antonio, Texas, United States

Investigational Site Number 840008

San Antonio, Texas, United States

Investigational Site Number 056001

Brussels, , Belgium

Investigational Site Number 056002

Ghent, , Belgium

Countries

United States; Belgium

References

Ogasawara K, Xu C, Yin J, Darpo B, Carayannopoulos L, Xue H, Palmisano M, Krishna G. Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors. Clin Pharmacol Drug Dev. 2021 Apr;10(4):366-375. doi: 10.1002/cpdd.850. Epub 2020 Jul 16.

Reference Type: DERIVED

PMID: 32673446 (View on PubMed)

Other Identifiers

2012-005642-38

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

U1111-1115-7323

Identifier Type: OTHER

Identifier Source: secondary_id

TES13519

Identifier Type: -

Identifier Source: org_study_id